A Multifactorial Trial Design to Assess Combination Therapy in Hypertension: Treatment With Bisoprolol and Hydrochlorothiazide

Archives of Internal Medicine

Volumn 154, Issue 13, 1994, Pages 1461-1468

  Frishman, William H ^a   Bryzinski, Brian S ^b   Coulson, Lewis R ^c   Dequattro, Vincent L ^d   Vlachakis, Nicolas D ^d   Mroczek, William J ^e   Dukart, Gary ^b   Goldberg, Judith D ^b   Alemayehu, Demissie ^b   Koury, Kenneth ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e Clinical Statistics American Cyanamid Co ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISOPROLOL; CALCIUM; CHOLESTEROL; GLUCOSE; HYDROCHLOROTHIAZIDE; POTASSIUM; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; HUMAN; HYPERKALEMIA; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; VERTIGO;

BISOPROLOL; BLOOD PRESSURE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 0028244265     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.1994.00420130048008     Document Type: Article

References (46)

1. The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure: a cooperative study. JAMA. 1977; 237:255-261.
2. The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1980 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1980; 140:1280-1285.
3. The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1984 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1984; 144:1045-1057.
4. 1988 Joint National Committee. The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1988;148:1023-1038.
5. The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
6. James IM. Which antihypertensive? Br J Clin Pract. 1990;44:102-105.
7. Townsend RR, Holland OB. Combination of converting enzyme inhibitor with diuretic for the treatment of hypertension. Arch Intern Med. 1990;150:1175-1183.
8. Fouad FM, Tarazi RC. Cardiac factors in response to antihypertensive treatment. Hypertension. 1983;5(suppl III):43-48.
9. Simpson FO. Combination therapy in hypertension. Drugs. 1980;20:69-73.
10. Enlund H, Turakka H, Tuomilehto J. Combination therapy in hypertension. Eur J Clin Pharmacol. 1981;21:1-8.
11. Shenfield GM. Fixed combination drug therapy. Drugs. 1982;23:462-480.
12. Oster JR, Epstein M. Fixed-dose combination medications for the treatment of hypertension: a critical review. J Clin Hypertens. 1987;3:278-293.
13. Weber MA, Drayer JM. Single-agent and combination therapy of essential hypertension. Am Heart J. 1984;108:311-316.
14. Brunner HR, Menard J, Waeber B, et al. Treating the individual hypertensive patient: considerations of dose, sequential monotherapy, and drug combinations. J Hypertens. 1990;8:3-11.
15. Dengler HJ, Lasagna L. Report of a workshop on fixed-ratio drug combinations. Eur J Clin Pharmacol. 1975;8:140-154.
16. Dollery CT. Pharmacological basis for combination therapy of hypertension. Annu Rev Pharmacol Toxicol. 1977;17:311-323.
17. Draft of the Proposed Guidelines for the Clinical Evaluation of Antihypertensive Drugs. Rockville, Md: Division of Cardio-Renal Drug Products, Food and Drug Administration; 1988.
18. Goldberg MR, Rockhold FW, Offen WW. Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension. Clin Pharmacol Ther. 1989;46:208-218.
19. Goldberg MR. Offen WW. Pinacidil with and without hydrochlorothiazide: doseresponse relationships from results of a 4×3 factorial design study. Drugs. 1988;36(suppl 7):83-92.
20. Burris JF, Weir MR, Oparil S, Weber M, Cady WJ, Stewart WH. An assessment of diltiazem and hydrochlorothiazide in hypertension: application of factorial trial design to a multicenter clinical trial of combination therapy. JAMA. 1990;263:1507-1512.
21. De Backer G, Kornitzer M, Dramaix M, et al. The Belgian Heart Disease Prevention Project: 10-year mortality follow-up. Eur Heart J. 1988;9:238-242.
22. Davis BR, Blaufox MD, Hawkins CM, et al. Trial of antihypertensive interventions and management. Controlled Clin Trials. 1989;10:11-30.
23. Snedecor GW, Cochran WG. Factorial experiments. In: Statistical Methods. Ames: Iowa State University Press; 1989;297-332.
24. Goldberg Mr, Offen WW, Rockhold FW, Factorial design: an approach to the assessment of therapeutic drug interactions in clinical trials. J Clin Res Drug Dev. 1988;2:215-225.
25. Pigeon JG, Copenhaver MD, Whipple JP. A method of designing clinical trials for combination drugs. Stat Med. 1992;2:1065-1074.
26. Chalmers TC. A potpourri of RCT topics. Controlled Clin Trials. 1982;3:285-298.
27. Bolli P, Buhler FR. Bisoprolol. In: Messerli FR, ed. Cardiovascular Drug Therapy. Philadelphia, Pa: WB Saunders Co; 1990:chap 43.
28. Lancaster SG, Sorkin EM. Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. Drugs. 1988;36:256-285.
29. Metropolitan Life Insurance Company. 1983 Metropolitan height and weight tables for men and women. Stat Bull Metrop Insur Co. 1983;64:2-9.
30. Skillings JH, Wolfe DA. Distribution-free tests for ordered alternatives in a randomized block design. J Am Stat Assoc. 1978;73:427-431.
31. Andren L, Weiner L, Svensson A, Hansson L. Enalapril with either a ‘very low’ or ‘low’ dose of hydrochlorothiazide is equally effective in essential hypertension: a double-blind trial in 100 hypertensive patients. J Hypertens. 1983;1 (suppl 2):384-386.
32. Ziegler MG, Lernhardt E, Solt-Buzsaki V. Dose response to hydrochlorothiazide in hypertensives receiving a calcium channel blocker. Clin Exp Hypertens A. 1988;A10:791-800.
33. Carlsen JE, Kober L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ. 1990;300:975-978.
34. Berglund G, Andersson O. Low doses of hydrochlorothiazide in hypertension: antihypertensive and metabolic effects. Eur J Clin Pharmacol. 1976;10:177-182.
35. Multiple Risk Factor Intervention Group. Baseline rest electrocardiographic abnormalities, antihypertensive treatment, and mortality in the multiple risk factor intervention trial. Am J Cardiol. 1985;55:1-5.
36. MacGregor GA, Banks RA, Markandu ND, Bayliss J, Roulston J. Lack of effect of beta-blocker on flat dose response to thiazide in hypertension: efficacy of low dose thiazide combined with beta-blocker. BMJ. 1983;286:1535-1538.
37. Hollifield JW, Slaton PE. Thiazide diuretics, hypokalemia, and cardiac arrhythmias. Acta Med Scand Suppl. 1981;647:67-73.
38. McVeigh G, Galloway D, Johnston D. The case for low dose diuretics in hypertension: comparison of low and conventional doses of cyclopenthiazide. BMJ. 1988;297:95-98.
39. Freis ED. Critique of the clinical importance of diuretic-induced hypokalemia and elevated cholesterol level. Arch Intern Med. 1989;149:2640-2648.
40. Kaplan NM. How bad are diuretic-induced hypokalemia and hypercholesterolemia? Arch Intern Med. 1989;149:2649.
41. Podrid PJ. Potassium and ventricular arrhythmias. Am J Cardiol. 1990;65: 33E-44E.
42. Houston MC, Johnston PE. Essential hypertension: new insights and controversies in treatment with diuretics. South Med J. 1986;79:984-990.
43. Grimm RH, Leon AS, Hunninghake LA, Lenz K, Hannan P, Blackburn H. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial. Ann Intern Med. 1981;94:7-11.
44. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Propranolol or hydrochlorothiazide alone for the initial treatment of hypertension, IV: effect on plasma glucose and glucose tolerance. Hypertension. 1985; 7:1008-1016.
45. Helgeland A, Leren P, Foss OP, Hjermann I, Holme I, Lund-Larsen PG. Serum glucose levels during long-term observation of treated and untreated men with mild hypertension: the Oslo Study. Am J Med. 1984;76:802-805.
46. Linden T, Camejo G, Wiklund O, Warnold I, Olofsson S, Bondjers G. Effect of short-term beta blockade on serum lipid levels and on the interaction of LDL with human arterial proteoglycans. J Clin Pharmacol. 1990;30:S124-S131.